- Page 1 and 2: The second edition of this practica
- Page 3 and 4: WHO Library Cataloguing-in-Publicat
- Page 5 and 6: 11. What is the additional yield fr
- Page 7 and 8: 46. What are the causes of drug-res
- Page 9 and 10: Preface to the First Edition One of
- Page 11 and 12: plementation of effective control s
- Page 13 and 14: TOMAN’S TUBERCULOSIS This second
- Page 15 and 16: Acknowledgements for the Second Edi
- Page 17 and 18: Contributors Rani Balasubramanian M
- Page 19 and 20: TOMAN’S TUBERCULOSIS Margarita El
- Page 22 and 23: 1. What is the role of case detecti
- Page 24 and 25: 2. What is a case of tuberculosis?
- Page 26 and 27: 3. What is the role of sputum micro
- Page 28 and 29: CASE DETECTION Case detection in ou
- Page 30 and 31: 4. How many bacilli are present in
- Page 34 and 35: CASE DETECTION Table 2 Number of ac
- Page 36 and 37: CASE DETECTION Table 4 Frequency of
- Page 38 and 39: CASE DETECTION (spot sample). The s
- Page 40 and 41: CASE DETECTION the peripheral healt
- Page 42 and 43: 6. What are the main causes of fals
- Page 44 and 45: CASE DETECTION with a swab may prov
- Page 46 and 47: CASE DETECTION 2. Smithwick RW. Lab
- Page 48 and 49: CASE DETECTION actually have tuberc
- Page 50 and 51: 8. What are the advantages and disa
- Page 52 and 53: Culture Fluorescence Total microsco
- Page 54 and 55: 9. What is the role of mycobacteria
- Page 56 and 57: CASE DETECTION Figure 1 Percentage
- Page 58 and 59: CASE DETECTION In a carefully condu
- Page 60 and 61: CASE DETECTION diagnosis. If availa
- Page 62 and 63: CASE DETECTION 8. Rao KP et al. Som
- Page 64 and 65: CASE DETECTION Table 12 Results of
- Page 66 and 67: CASE DETECTION Table 13 Results of
- Page 68 and 69: CASE DETECTION Among patients in wh
- Page 70 and 71: 12. How reliable is chest radiograp
- Page 72 and 73: CASE DETECTION Table 16 Observer er
- Page 74 and 75: CASE DETECTION patients with previo
- Page 76 and 77: CASE DETECTION Figure 4 Examples of
- Page 78 and 79: chest radiograph as the diagnostic
- Page 80 and 81: 13. What are the relative merits of
- Page 82 and 83:
CASE DETECTION Table 21 Correlation
- Page 84 and 85:
CASE DETECTION tries, this delay le
- Page 86 and 87:
CASE DETECTION Table 22 Interval be
- Page 88 and 89:
CASE DETECTION However, even in the
- Page 90 and 91:
CASE DETECTION 7. Douglas BH, Pinne
- Page 92 and 93:
CASE DETECTION Figure 5 Risk of inf
- Page 94 and 95:
CASE DETECTION Table 23 Mode of det
- Page 96 and 97:
CASE DETECTION Figure 8 Cumulative
- Page 98 and 99:
CASE DETECTION Czechoslovakia. Seco
- Page 100 and 101:
CASE DETECTION Figure 9 Radiographi
- Page 102 and 103:
CASE DETECTION 4. Harries AD. Tuber
- Page 104 and 105:
CASE DETECTION BCG is given in infa
- Page 106 and 107:
18. What is the current and potenti
- Page 108 and 109:
CASE DETECTION currently performed
- Page 110 and 111:
CASE DETECTION 13. Holden M, Dubin
- Page 112 and 113:
Exclusion CASE DETECTION Another ap
- Page 114:
CASE DETECTION 6. Khatri GR, Friede
- Page 118 and 119:
20. What were the main landmarks in
- Page 120 and 121:
TREATMENT 2. WHO Expert Committee o
- Page 122 and 123:
TREATMENT present even before treat
- Page 124 and 125:
TREATMENT 2. Furesz S et al. Rifamp
- Page 126 and 127:
TREATMENT Table 25 Incidence of tub
- Page 128 and 129:
TREATMENT 3. Holmes CB, Hausler H,
- Page 130 and 131:
TREATMENT The time during which an
- Page 132 and 133:
TREATMENT The “flu” syndrome, w
- Page 134 and 135:
Streptomycin TREATMENT Isolated by
- Page 136 and 137:
Capreomycin TREATMENT Capreomycin i
- Page 138 and 139:
valuable in preventing resistance t
- Page 140 and 141:
TREATMENT 13. Skolnick JL et al. Ri
- Page 142 and 143:
TREATMENT Thus the emergence of new
- Page 144 and 145:
TREATMENT Table 27 Recommended trea
- Page 146 and 147:
TREATMENT toxicity, particularly in
- Page 148 and 149:
TREATMENT drug-resistant organisms
- Page 150 and 151:
TREATMENT Table 28 Lag in growth of
- Page 152 and 153:
TREATMENT Table 30 Comparison of re
- Page 154 and 155:
TREATMENT Table 32 Studies using pa
- Page 156 and 157:
TREATMENT tuberculosis in the forme
- Page 158 and 159:
28. What is the dosage of drugs in
- Page 160 and 161:
29. What is the evidence for tuberc
- Page 162 and 163:
TREATMENT 4. Acocella G. Clinical p
- Page 164 and 165:
TREATMENT Table 35 Duration of trea
- Page 166 and 167:
TREATMENT concluded that smear-nega
- Page 168 and 169:
TREATMENT Table 41 Response to trea
- Page 170 and 171:
TREATMENT National Tuberculosis Ins
- Page 172 and 173:
Rare adverse effects ● Osteomalac
- Page 174 and 175:
Management ● For minor adverse ef
- Page 176 and 177:
TREATMENT Management of jaundice an
- Page 178 and 179:
32. What are the merits of thioacet
- Page 180 and 181:
always receive at least two drugs (
- Page 182 and 183:
TREATMENT culosis, and brain tuberc
- Page 184 and 185:
References TREATMENT 1. Ramanathan
- Page 186 and 187:
TREATMENT If a tuberculin skin test
- Page 188 and 189:
35. How does treatment of tuberculo
- Page 190 and 191:
TREATMENT being part of the immune
- Page 192 and 193:
36. What were the main findings of
- Page 194 and 195:
TREATMENT decoded by the Centre’s
- Page 196 and 197:
TREATMENT Table 45 Quiescence of di
- Page 198 and 199:
TREATMENT Summary In a controlled c
- Page 200 and 201:
37. How frequently do patients stop
- Page 202 and 203:
38. What are the advantages of dire
- Page 204 and 205:
39. Why does treatment fail and wha
- Page 206 and 207:
TREATMENT duration of treatment, es
- Page 208 and 209:
40. What are the advantages and dis
- Page 210 and 211:
TREATMENT ● There is a theoretica
- Page 212 and 213:
41. How does drug resistance develo
- Page 214 and 215:
42. Why are special precautions nee
- Page 216 and 217:
TREATMENT 2. Espinal MA et al. Stan
- Page 218 and 219:
TREATMENT past. This type of drug r
- Page 220 and 221:
Figure 16 The “fall and rise” p
- Page 222 and 223:
45. How many drug-resistant tubercl
- Page 224 and 225:
TREATMENT Table 50 Estimated number
- Page 226 and 227:
46. What are the causes of drug-res
- Page 228 and 229:
47. How can the emergence of drug r
- Page 230 and 231:
48. How reliable are drug susceptib
- Page 232 and 233:
49. What are the possible consequen
- Page 234 and 235:
50. What reserve regimens are avail
- Page 236 and 237:
TREATMENT countries, using reserve
- Page 238 and 239:
TREATMENT 5. Guidelines for establi
- Page 240 and 241:
TREATMENT Before a decision is made
- Page 242 and 243:
TREATMENT Table 53 Management of ch
- Page 244 and 245:
TREATMENT egy should be reserved fo
- Page 246 and 247:
TREATMENT Table 54 Results of commu
- Page 248:
TREATMENT 10. Barnes PF et al. Tran
- Page 252 and 253:
53. What is the health, social, and
- Page 254 and 255:
MONITORING Table 55 Estimated house
- Page 256 and 257:
MONITORING 14. Saunderson PR. An ec
- Page 258 and 259:
MONITORING tion in prevalence over
- Page 260 and 261:
55. What is DOTS? I. Smith 1 DOTS i
- Page 262 and 263:
MONITORING observation to once a we
- Page 264 and 265:
MONITORING targets (17). Successful
- Page 266 and 267:
MONITORING Figure 19 Theoretical fr
- Page 268 and 269:
MONITORING tributed US$ 229 in dire
- Page 270 and 271:
MONITORING Table 58 Interpretation
- Page 272 and 273:
58. How effective is tuberculosis t
- Page 274 and 275:
MONITORING sufficient proportion of
- Page 276 and 277:
MONITORING Figure 20 Countries/area
- Page 278 and 279:
MONITORING ing a greater danger to
- Page 280 and 281:
MONITORING Even the most effective
- Page 282 and 283:
61. What is the significance of def
- Page 284 and 285:
MONITORING problems, way of life, w
- Page 286 and 287:
62. How important is follow-up and
- Page 288 and 289:
References MONITORING 1. Revised in
- Page 290 and 291:
MONITORING proportion of patients e
- Page 292 and 293:
MONITORING 4. Enarson D et al. Mana
- Page 294 and 295:
MONITORING contacts of the tubercul
- Page 296 and 297:
MONITORING 13. Brooks SM, Lassiter
- Page 298 and 299:
MONITORING Administrative controls
- Page 300 and 301:
MONITORING 5. Frieden TR et al. A m
- Page 302 and 303:
MONITORING M. tuberculosis is thus
- Page 304 and 305:
67. What are the principles and req
- Page 306 and 307:
MONITORING is not supported by quan
- Page 308 and 309:
MONITORING treatment (see “What w
- Page 310 and 311:
MONITORING A satisfactory randomiza
- Page 312 and 313:
MONITORING pendent readers, if poss
- Page 314 and 315:
MONITORING a new treatment. The dra
- Page 316 and 317:
MONITORING importantly, molecular a
- Page 318 and 319:
MONITORING 4. García-García M et
- Page 320 and 321:
69. Can tuberculosis be controlled?
- Page 322 and 323:
Prevalence of disease Prevalence of
- Page 324 and 325:
MONITORING difficult and are furthe
- Page 326 and 327:
MONITORING blunt the impact of this
- Page 328 and 329:
MONITORING ation with an emphasis o
- Page 330 and 331:
MONITORING tively) and have achieve
- Page 332 and 333:
MONITORING and shelters for the hom
- Page 334 and 335:
71. What are the indicators of an e
- Page 336 and 337:
MONITORING only after several years
- Page 338 and 339:
MONITORING More importantly, there
- Page 340 and 341:
MONITORING 10. Results of directly
- Page 342 and 343:
MONITORING ● Expansion of the lab
- Page 344 and 345:
Monitoring (including research) ●
- Page 346 and 347:
MONITORING personnel; there is an i
- Page 348 and 349:
MONITORING 5. Global tuberculosis c
- Page 350 and 351:
MONITORING who fund and support the